-$1.36 EPS Expected for Clovis Oncology (CLVS) This Quarter

Share on StockTwits

Wall Street brokerages expect that Clovis Oncology (NASDAQ:CLVS) will report earnings of ($1.36) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Clovis Oncology’s earnings. The lowest EPS estimate is ($1.43) and the highest is ($1.30). Clovis Oncology posted earnings of ($1.29) per share during the same quarter last year, which suggests a negative year over year growth rate of 5.4%. The company is expected to report its next earnings report on Wednesday, August 1st.

On average, analysts expect that Clovis Oncology will report full-year earnings of ($5.30) per share for the current fiscal year, with EPS estimates ranging from ($5.87) to ($4.82). For the next financial year, analysts anticipate that the company will report earnings of ($3.48) per share, with EPS estimates ranging from ($4.81) to ($2.20). Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Clovis Oncology.

Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.18). The company had revenue of $18.50 million during the quarter, compared to analysts’ expectations of $18.34 million. Clovis Oncology had a negative net margin of 545.80% and a negative return on equity of 79.02%. Clovis Oncology’s revenue for the quarter was up 164.3% on a year-over-year basis. During the same quarter last year, the company earned ($1.33) earnings per share.

A number of equities research analysts have recently issued reports on CLVS shares. SunTrust Banks dropped their price target on Clovis Oncology from $95.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Stifel Nicolaus lowered their price objective on Clovis Oncology from $125.00 to $110.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Barclays set a $85.00 price objective on Clovis Oncology and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Credit Suisse Group set a $86.00 price objective on Clovis Oncology and gave the stock a “buy” rating in a research report on Friday, April 6th. Finally, Bank of America lowered their price objective on Clovis Oncology from $90.00 to $55.52 and set a “buy” rating for the company in a research report on Monday, April 9th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and thirteen have given a buy rating to the company. Clovis Oncology currently has a consensus rating of “Buy” and an average price target of $84.09.

CLVS stock opened at $48.65 on Wednesday. The company has a quick ratio of 5.74, a current ratio of 6.55 and a debt-to-equity ratio of 0.92. The company has a market capitalization of $2.49 billion, a PE ratio of -9.50 and a beta of 0.94. Clovis Oncology has a 1 year low of $41.31 and a 1 year high of $99.45.

In other news, Director Thorlef Spickschen sold 4,500 shares of the firm’s stock in a transaction on Monday, April 9th. The stock was sold at an average price of $60.02, for a total transaction of $270,090.00. Following the completion of the transaction, the director now directly owns 7,618 shares in the company, valued at $457,232.36. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 10.20% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CLVS. Schwab Charles Investment Management Inc. boosted its position in shares of Clovis Oncology by 5.3% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 220,924 shares of the biopharmaceutical company’s stock worth $15,023,000 after buying an additional 11,030 shares during the period. Teacher Retirement System of Texas boosted its position in shares of Clovis Oncology by 311.8% during the fourth quarter. Teacher Retirement System of Texas now owns 15,644 shares of the biopharmaceutical company’s stock worth $1,064,000 after buying an additional 11,845 shares during the period. California Public Employees Retirement System raised its stake in shares of Clovis Oncology by 191.1% in the fourth quarter. California Public Employees Retirement System now owns 97,184 shares of the biopharmaceutical company’s stock valued at $6,609,000 after acquiring an additional 63,800 shares in the last quarter. Swiss National Bank raised its stake in shares of Clovis Oncology by 3.4% in the fourth quarter. Swiss National Bank now owns 79,050 shares of the biopharmaceutical company’s stock valued at $5,375,000 after acquiring an additional 2,600 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. raised its stake in shares of Clovis Oncology by 662.3% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 21,565 shares of the biopharmaceutical company’s stock valued at $1,466,000 after acquiring an additional 25,400 shares in the last quarter. Institutional investors and hedge funds own 93.98% of the company’s stock.

About Clovis Oncology

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Get a free copy of the Zacks research report on Clovis Oncology (CLVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply